Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry LeadersThe Motley Fool • 12/29/24
FDA approves first medication for obstructive sleep apnea — which also promotes weight lossNew York Post • 12/25/24
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and MoreBenzinga • 12/22/24
Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?Investors Business Daily • 12/20/24
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.CNBC • 12/20/24
FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesityPRNewsWire • 12/20/24
Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must NowSeeking Alpha • 12/20/24